Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A)

Eric C Truong, Puay W Phuan, Amanda L Reggi, Loretta Ferrera, Luis J V Galietta, Sarah E Levy, Alannah C Moises, Onur Cil, Elena Diez-Cecilia, Sujin Lee, Alan S Verkman, Marc O Anderson

Research output: Contribution to journalArticle

Abstract

Transmembrane protein 16A (TMEM16A), also called anoctamin 1 (ANO1), is a calcium-activated chloride channel expressed widely mammalian cells, including epithelia, vascular smooth muscle tissue, electrically excitable cells, and some tumors. TMEM16A inhibitors have been proposed for treatment of disorders of epithelial fluid and mucus secretion, hypertension, asthma, and possibly cancer. Herein we report, by screening, the discovery of 2-acylaminocycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as inhibitors of TMEM16A and analysis of 48 synthesized analogs (10ab-10bw) of the original AACT compound (10aa). Structure-activity studies indicated the importance of benzene substituted as 2- or 4-methyl, or 4-fluoro, and defined the significance of thiophene substituents and size of the cycloalkylthiophene core. The most potent compound (10bm), which contains an unusual bromodifluoroacetamide at the thiophene 2-position, had IC50 of ∼30 nM, ∼3.6-fold more potent than the most potent previously reported TMEM16A inhibitor 4 (Ani9), and >10-fold improved metabolic stability. Direct and reversible inhibition of TMEM16A by 10bm was demonstrated by patch-clamp analysis. AACTs may be useful as pharmacological tools to study TMEM16A function and as potential drug development candidates.

Original languageEnglish
Pages (from-to)4626-4635
Number of pages10
JournalJournal of Medicinal Chemistry
Volume60
Issue number11
DOIs
Publication statusPublished - Jun 8 2017

Fingerprint

Chloride Channels
Carboxylic Acids
Thiophenes
Proteins
Fluids and Secretions
Mucus
Benzene
Vascular Smooth Muscle
Inhibitory Concentration 50
Neoplasms
Asthma
Epithelium
Pharmacology
Hypertension
Muscles
Pharmaceutical Preparations

Keywords

  • Animals
  • Anoctamin-1
  • Carboxylic Acids
  • Cells, Cultured
  • Chloride Channels
  • Humans
  • Rats
  • Rats, Inbred F344
  • Structure-Activity Relationship
  • Thiophenes
  • Journal Article

Cite this

Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A). / Truong, Eric C; Phuan, Puay W; Reggi, Amanda L; Ferrera, Loretta; Galietta, Luis J V; Levy, Sarah E; Moises, Alannah C; Cil, Onur; Diez-Cecilia, Elena; Lee, Sujin; Verkman, Alan S; Anderson, Marc O.

In: Journal of Medicinal Chemistry, Vol. 60, No. 11, 08.06.2017, p. 4626-4635.

Research output: Contribution to journalArticle

Truong, EC, Phuan, PW, Reggi, AL, Ferrera, L, Galietta, LJV, Levy, SE, Moises, AC, Cil, O, Diez-Cecilia, E, Lee, S, Verkman, AS & Anderson, MO 2017, 'Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A)', Journal of Medicinal Chemistry, vol. 60, no. 11, pp. 4626-4635. https://doi.org/10.1021/acs.jmedchem.7b00020
Truong, Eric C ; Phuan, Puay W ; Reggi, Amanda L ; Ferrera, Loretta ; Galietta, Luis J V ; Levy, Sarah E ; Moises, Alannah C ; Cil, Onur ; Diez-Cecilia, Elena ; Lee, Sujin ; Verkman, Alan S ; Anderson, Marc O. / Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A). In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 11. pp. 4626-4635.
@article{8dce656771044d028ba6e6ce8d0cbdf0,
title = "Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A)",
abstract = "Transmembrane protein 16A (TMEM16A), also called anoctamin 1 (ANO1), is a calcium-activated chloride channel expressed widely mammalian cells, including epithelia, vascular smooth muscle tissue, electrically excitable cells, and some tumors. TMEM16A inhibitors have been proposed for treatment of disorders of epithelial fluid and mucus secretion, hypertension, asthma, and possibly cancer. Herein we report, by screening, the discovery of 2-acylaminocycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as inhibitors of TMEM16A and analysis of 48 synthesized analogs (10ab-10bw) of the original AACT compound (10aa). Structure-activity studies indicated the importance of benzene substituted as 2- or 4-methyl, or 4-fluoro, and defined the significance of thiophene substituents and size of the cycloalkylthiophene core. The most potent compound (10bm), which contains an unusual bromodifluoroacetamide at the thiophene 2-position, had IC50 of ∼30 nM, ∼3.6-fold more potent than the most potent previously reported TMEM16A inhibitor 4 (Ani9), and >10-fold improved metabolic stability. Direct and reversible inhibition of TMEM16A by 10bm was demonstrated by patch-clamp analysis. AACTs may be useful as pharmacological tools to study TMEM16A function and as potential drug development candidates.",
keywords = "Animals, Anoctamin-1, Carboxylic Acids, Cells, Cultured, Chloride Channels, Humans, Rats, Rats, Inbred F344, Structure-Activity Relationship, Thiophenes, Journal Article",
author = "Truong, {Eric C} and Phuan, {Puay W} and Reggi, {Amanda L} and Loretta Ferrera and Galietta, {Luis J V} and Levy, {Sarah E} and Moises, {Alannah C} and Onur Cil and Elena Diez-Cecilia and Sujin Lee and Verkman, {Alan S} and Anderson, {Marc O}",
year = "2017",
month = "6",
day = "8",
doi = "10.1021/acs.jmedchem.7b00020",
language = "English",
volume = "60",
pages = "4626--4635",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A)

AU - Truong, Eric C

AU - Phuan, Puay W

AU - Reggi, Amanda L

AU - Ferrera, Loretta

AU - Galietta, Luis J V

AU - Levy, Sarah E

AU - Moises, Alannah C

AU - Cil, Onur

AU - Diez-Cecilia, Elena

AU - Lee, Sujin

AU - Verkman, Alan S

AU - Anderson, Marc O

PY - 2017/6/8

Y1 - 2017/6/8

N2 - Transmembrane protein 16A (TMEM16A), also called anoctamin 1 (ANO1), is a calcium-activated chloride channel expressed widely mammalian cells, including epithelia, vascular smooth muscle tissue, electrically excitable cells, and some tumors. TMEM16A inhibitors have been proposed for treatment of disorders of epithelial fluid and mucus secretion, hypertension, asthma, and possibly cancer. Herein we report, by screening, the discovery of 2-acylaminocycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as inhibitors of TMEM16A and analysis of 48 synthesized analogs (10ab-10bw) of the original AACT compound (10aa). Structure-activity studies indicated the importance of benzene substituted as 2- or 4-methyl, or 4-fluoro, and defined the significance of thiophene substituents and size of the cycloalkylthiophene core. The most potent compound (10bm), which contains an unusual bromodifluoroacetamide at the thiophene 2-position, had IC50 of ∼30 nM, ∼3.6-fold more potent than the most potent previously reported TMEM16A inhibitor 4 (Ani9), and >10-fold improved metabolic stability. Direct and reversible inhibition of TMEM16A by 10bm was demonstrated by patch-clamp analysis. AACTs may be useful as pharmacological tools to study TMEM16A function and as potential drug development candidates.

AB - Transmembrane protein 16A (TMEM16A), also called anoctamin 1 (ANO1), is a calcium-activated chloride channel expressed widely mammalian cells, including epithelia, vascular smooth muscle tissue, electrically excitable cells, and some tumors. TMEM16A inhibitors have been proposed for treatment of disorders of epithelial fluid and mucus secretion, hypertension, asthma, and possibly cancer. Herein we report, by screening, the discovery of 2-acylaminocycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as inhibitors of TMEM16A and analysis of 48 synthesized analogs (10ab-10bw) of the original AACT compound (10aa). Structure-activity studies indicated the importance of benzene substituted as 2- or 4-methyl, or 4-fluoro, and defined the significance of thiophene substituents and size of the cycloalkylthiophene core. The most potent compound (10bm), which contains an unusual bromodifluoroacetamide at the thiophene 2-position, had IC50 of ∼30 nM, ∼3.6-fold more potent than the most potent previously reported TMEM16A inhibitor 4 (Ani9), and >10-fold improved metabolic stability. Direct and reversible inhibition of TMEM16A by 10bm was demonstrated by patch-clamp analysis. AACTs may be useful as pharmacological tools to study TMEM16A function and as potential drug development candidates.

KW - Animals

KW - Anoctamin-1

KW - Carboxylic Acids

KW - Cells, Cultured

KW - Chloride Channels

KW - Humans

KW - Rats

KW - Rats, Inbred F344

KW - Structure-Activity Relationship

KW - Thiophenes

KW - Journal Article

U2 - 10.1021/acs.jmedchem.7b00020

DO - 10.1021/acs.jmedchem.7b00020

M3 - Article

C2 - 28493701

VL - 60

SP - 4626

EP - 4635

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 11

ER -